192 related articles for article (PubMed ID: 35525797)
1. Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy.
Lammoglia Cobo MF; Welters C; Rosenberger L; Leisegang M; Dietze K; Pircher C; Penter L; Gary R; Bullinger L; Takvorian A; Moosmann A; Dornmair K; Blankenstein T; Kammertöns T; Gerbitz A; Hansmann L
Cytotherapy; 2022 Aug; 24(8):818-826. PubMed ID: 35525797
[TBL] [Abstract][Full Text] [Related]
2. Identification of Functional HLA-A*01:01-Restricted Epstein-Barr Latent Membrane Protein 2-Specific T-Cell Receptors.
Huisman W; Gille I; van der Maarel LE; Hageman L; Morton LT; de Jong RCM; Heemskerk MHM; Amsen D; Falkenburg JHF; Jedema I
J Infect Dis; 2022 Sep; 226(5):833-842. PubMed ID: 32808978
[TBL] [Abstract][Full Text] [Related]
3. Generation of Epstein-Barr Virus Antigen-Specific T Cell Receptors Recognizing Immunodominant Epitopes of LMP1, LMP2A, and EBNA3C for Immunotherapy.
Dudaniec K; Westendorf K; Nössner E; Uckert W
Hum Gene Ther; 2021 Sep; 32(17-18):919-935. PubMed ID: 33798008
[TBL] [Abstract][Full Text] [Related]
4. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
5. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
6. Cross-reactivity influences changes in human influenza A virus and Epstein Barr virus specific CD8 memory T cell receptor alpha and beta repertoires between young and old.
Clark F; Gil A; Thapa I; Aslan N; Ghersi D; Selin LK
Front Immunol; 2022; 13():1011935. PubMed ID: 36923729
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
8. Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL.
Lammoglia Cobo MF; Ritter J; Gary R; Seitz V; Mautner J; Aigner M; Völkl S; Schaffer S; Moi S; Seegebarth A; Bruns H; Rösler W; Amann K; Büttner-Herold M; Hennig S; Mackensen A; Hummel M; Moosmann A; Gerbitz A
PLoS Pathog; 2022 Apr; 18(4):e1010206. PubMed ID: 35452490
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
10. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB
J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456
[TBL] [Abstract][Full Text] [Related]
11. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524
[TBL] [Abstract][Full Text] [Related]
12. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
13. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.
Marshall NA; Howe JG; Formica R; Krause D; Wagner JE; Berliner N; Crouch J; Pilip I; Cooper D; Blazar BR; Seropian S; Pamer EG
Blood; 2000 Oct; 96(8):2814-21. PubMed ID: 11023516
[TBL] [Abstract][Full Text] [Related]
14. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity.
Burrows SR; Silins SL; Khanna R; Burrows JM; Rischmueller M; McCluskey J; Moss DJ
Eur J Immunol; 1997 Jul; 27(7):1726-36. PubMed ID: 9247584
[TBL] [Abstract][Full Text] [Related]
15. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
16. Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors.
Sooda A; Rwandamuriye F; Wanjalla CN; Jing L; Koelle DM; Peters B; Leary S; Chopra A; Calderwood MA; Mallal SA; Pavlos R; Watson M; Phillips EJ; Redwood AJ
Commun Biol; 2022 Feb; 5(1):133. PubMed ID: 35173258
[TBL] [Abstract][Full Text] [Related]
17. Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection.
Catalina MD; Sullivan JL; Bak KR; Luzuriaga K
J Immunol; 2001 Oct; 167(8):4450-7. PubMed ID: 11591771
[TBL] [Abstract][Full Text] [Related]
18. Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis.
Silins SL; Cross SM; Elliott SL; Pye SJ; Burrows SR; Burrows JM; Moss DJ; Argaet VP; Misko IS
J Exp Med; 1996 Nov; 184(5):1815-24. PubMed ID: 8920869
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
[TBL] [Abstract][Full Text] [Related]
20. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
